Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery

Neuroscience Letters

Volumn 543, Issue , 2013, Pages 52-57

  Park, Tae Yoon ^a   Shin, Min Jung ^a   Park, Sung Dong ^a   Lee, Sang Kyou ^a  

^a Yonsei University   (South Korea)

Author keywords

Anti wrinkle; Botulinum neurotoxin; Drug delivery; SNARE complex; Trans X

Indexed keywords

BOTULINUM TOXIN A; SYNAPTOBREVIN 2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TRANS X; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE RELEASE; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; COMPETITIVE INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; EXOCYTOSIS; EXPERIMENTAL RABBIT; FEMALE; HUMAN; MALE; MOUSE; MUSCLE ACTION POTENTIAL; MUSCLE FIBER CONTRACTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; SKIN ABRASION; SKIN PENETRATION; SKIN ROUGHNESS; SKIN SENSITIZATION; TRANSDERMAL PATCH; WRINKLE;

ACTION POTENTIALS; ADMINISTRATION, CUTANEOUS; ADULT; ANIMALS; CATECHOLAMINES; CELL LINE; CELL MEMBRANE PERMEABILITY; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; KERATINOCYTES; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MUSCLE, SKELETAL; NEUROTRANSMITTER AGENTS; PARALYSIS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RATS; RECOMBINANT FUSION PROTEINS; SKIN ABSORPTION; SKIN AGING; SWINE; SYNAPSES; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

EID: 84877106597     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.055     Document Type: Article

References (12)

1. Arthurs B., Flanders M., Codere F., Gauthier S., Dresner S., Stone L. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can. J. Ophthalmol. 1987, 22:24-28.
2. Bakheit A.M. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr. Drug. Saf. 2006, 1:271-279.
3. Calakos N., Bennett M.K., Peterson K.E., Scheller R.H. Protein-protein interactions contributing to the specificity of intracellular vesicular trafficking. Science 1994, 263:1146-1149.
4. Carruthers A., Carruthers J. History of the cosmetic use of botulinum A exotoxin. Dermatol. Surg. 1998, 24:1168-1170.
5. Choi J.M., Ahn M.H., Chae W.J., Jung Y.G., Park J.C., Song H.M., Kim Y.E., Shin J.A., Park C.S., Park J.W., Park T.K., Lee J.H., Seo B.F., Kim K.D., Kim E.S., Lee D.H., Lee S.K. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat. Med. 2006, 12:574-579.
6. Corradini I., Verderio C., Sala M., Wilson M.C., Matteoli M. SNAP-25 in neuropsychiatric disorders. Ann. N. Y. Acad. Sci. 2009, 1152:93-99.
7. Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nat. Clin. Pract. Neurol. 2008, 4:676-685.
8. Lee S.W., Kim J.H., Park M.C., Park Y.B., Chae W.J., Morio T., Lee D.H., Yang S.H., Lee S.K., Lee S.K., Lee S.K. Alleviation of rheumatoid arthritis by cell-transducible methotrexate upon transcutaneous delivery. Biomaterials 2012, 33:1563-1572.
9. Li L., Chin L.S. The molecular machinery of synaptic vesicle exocytosis. Cell. Mol. Life Sci. 2003, 60:942-960.
10. Lopes L.B., Furnish E., Komalavilas P., Seal B.L., Panitch A., Bentley M.V., Brophy C.M. Enhanced skin penetration of P20 phosphopeptide using protein transduction domains. Eur. J. Pharm. Biopharm. 2008, 68:441-445.
11. Nemeth A.H. The genetics of primary dystonias and related disorders. Brain 2002, 125:695-721.
12. Pevsner J., Hsu S.C., Braun J.E., Calakos N., Ting A.E., Bennett M.K., Scheller R.H. Specificity and regulation of a synaptic vesicle docking complex. Neuron 1994, 13:353-361.